Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation
In this work, heat stable dry powders of oxytocin (OT) suitable for delivery by oral inhalation were prepared. The OT dry powders were prepared by spray drying using excipients chosen to promote OT stability including trehalose, isoleucine, polyvinylpyrrolidone, citrate (sodium citrate and citric ac...
Gespeichert in:
Veröffentlicht in: | AAPS PharmSciTech 2015-12, Vol.16 (6), p.1299-1306 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1306 |
---|---|
container_issue | 6 |
container_start_page | 1299 |
container_title | AAPS PharmSciTech |
container_volume | 16 |
creator | Fabio, Karine Curley, Kieran Guarneri, Joseph Adamo, Benoit Laurenzi, Brendan Grant, Marshall Offord, Robin Kraft, Kelly Leone-Bay, Andrea |
description | In this work, heat stable dry powders of oxytocin (OT) suitable for delivery by oral inhalation were prepared. The OT dry powders were prepared by spray drying using excipients chosen to promote OT stability including trehalose, isoleucine, polyvinylpyrrolidone, citrate (sodium citrate and citric acid), and zinc salts (zinc chloride and zinc citrate). Characterization by laser diffraction indicated that the OT dry powders had a median particle size of 2 μm, making them suitable for delivery by inhalation. Aerodynamic performance upon discharge from proprietary dry powder inhalers was evaluated by Andersen cascade impaction (ACI) and in an anatomically correct airway (ACA) model, and confirmed that the powders had excellent aerodynamic performance, with respirable fractions up to 77% (ACI, 30 L/min). Physicochemical characterization demonstrated that the powders were amorphous (X-ray diffraction) with high glass transition temperature (modulated differential scanning calorimetry, MDSC), suggesting the potential for stabilization of the OT in a glassy amorphous matrix. OT assay and impurity profile were conducted by reverse phase HPLC and liquid chromatography-mass spectrometry (LC-MS) after storage up to 32 weeks at 40°C/75%RH. Analysis demonstrated that OT dry powders containing a mixture of citrate and zinc salts retained more than 90% of initial assay after 32 weeks storage and showed significant reduction in dimers and trisulfide formation (up to threefold reduction compared to control). |
doi_str_mv | 10.1208/s12249-015-0314-0 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4666249</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1787975827</sourcerecordid><originalsourceid>FETCH-LOGICAL-c545t-dbbe7469dfb599d449b14b17ac546092680e20f29c06d34c754fd3a2fdddf5103</originalsourceid><addsrcrecordid>eNqNkU9Lw0AQxRdRrFY_gBfJ0Ut0_2azF0HU2kKhgnpeNtlNm5Jm626i5tu7JbXUi3iagfebx8w8AC4QvEYYpjceYUxFDBGLIUE0hgfgBDECYyEIPtzrB-DU-yWEmCBBjsEAM84TkbITMB0b1cQvjcoqEz24Lnq2n9q4aPbVNTYv62hk3aqtVFPa2keFddGDqcoPE8isi2ZOVdGkXqgeOANHhaq8Od_WIXgbPb7ej-Pp7GlyfzeNc0ZZE-ssM5wmQhcZE0JTKjJEM8RVkBMocJJCg2GBRQ4TTWjOGS00UbjQWhcMQTIEt73vus1WRuembsIicu3KlXKdtKqUv5W6XMi5_ZA0SZLwsWBwtTVw9r01vpGr0uemqlRtbOsl4ikXnKWY_wMlaYpxSnBAUY_mznrvTLHbCEG5CUz2gckQmNwEJjenXO6fspv4SSgAuAd8kOq5cXJpW1eH9_7h-g30d6Fp</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1738822832</pqid></control><display><type>article</type><title>Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Fabio, Karine ; Curley, Kieran ; Guarneri, Joseph ; Adamo, Benoit ; Laurenzi, Brendan ; Grant, Marshall ; Offord, Robin ; Kraft, Kelly ; Leone-Bay, Andrea</creator><creatorcontrib>Fabio, Karine ; Curley, Kieran ; Guarneri, Joseph ; Adamo, Benoit ; Laurenzi, Brendan ; Grant, Marshall ; Offord, Robin ; Kraft, Kelly ; Leone-Bay, Andrea</creatorcontrib><description>In this work, heat stable dry powders of oxytocin (OT) suitable for delivery by oral inhalation were prepared. The OT dry powders were prepared by spray drying using excipients chosen to promote OT stability including trehalose, isoleucine, polyvinylpyrrolidone, citrate (sodium citrate and citric acid), and zinc salts (zinc chloride and zinc citrate). Characterization by laser diffraction indicated that the OT dry powders had a median particle size of 2 μm, making them suitable for delivery by inhalation. Aerodynamic performance upon discharge from proprietary dry powder inhalers was evaluated by Andersen cascade impaction (ACI) and in an anatomically correct airway (ACA) model, and confirmed that the powders had excellent aerodynamic performance, with respirable fractions up to 77% (ACI, 30 L/min). Physicochemical characterization demonstrated that the powders were amorphous (X-ray diffraction) with high glass transition temperature (modulated differential scanning calorimetry, MDSC), suggesting the potential for stabilization of the OT in a glassy amorphous matrix. OT assay and impurity profile were conducted by reverse phase HPLC and liquid chromatography-mass spectrometry (LC-MS) after storage up to 32 weeks at 40°C/75%RH. Analysis demonstrated that OT dry powders containing a mixture of citrate and zinc salts retained more than 90% of initial assay after 32 weeks storage and showed significant reduction in dimers and trisulfide formation (up to threefold reduction compared to control).</description><identifier>ISSN: 1530-9932</identifier><identifier>EISSN: 1530-9932</identifier><identifier>DOI: 10.1208/s12249-015-0314-0</identifier><identifier>PMID: 25776985</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Administration, Inhalation ; Aerosols - chemistry ; Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Biotechnology ; Calorimetry, Differential Scanning - methods ; Chemistry, Pharmaceutical - methods ; Desiccation - methods ; Drug Compounding - methods ; Drug Stability ; Dry Powder Inhalers - methods ; Excipients - chemistry ; Hot Temperature ; Nanoparticles - chemistry ; Oxytocin - chemistry ; Particle Size ; Pharmacology/Toxicology ; Pharmacy ; Powders - chemistry ; Research Article ; Trehalose - chemistry ; X-Ray Diffraction - methods</subject><ispartof>AAPS PharmSciTech, 2015-12, Vol.16 (6), p.1299-1306</ispartof><rights>American Association of Pharmaceutical Scientists 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c545t-dbbe7469dfb599d449b14b17ac546092680e20f29c06d34c754fd3a2fdddf5103</citedby><cites>FETCH-LOGICAL-c545t-dbbe7469dfb599d449b14b17ac546092680e20f29c06d34c754fd3a2fdddf5103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666249/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666249/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,41467,42536,51298,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25776985$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fabio, Karine</creatorcontrib><creatorcontrib>Curley, Kieran</creatorcontrib><creatorcontrib>Guarneri, Joseph</creatorcontrib><creatorcontrib>Adamo, Benoit</creatorcontrib><creatorcontrib>Laurenzi, Brendan</creatorcontrib><creatorcontrib>Grant, Marshall</creatorcontrib><creatorcontrib>Offord, Robin</creatorcontrib><creatorcontrib>Kraft, Kelly</creatorcontrib><creatorcontrib>Leone-Bay, Andrea</creatorcontrib><title>Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation</title><title>AAPS PharmSciTech</title><addtitle>AAPS PharmSciTech</addtitle><addtitle>AAPS PharmSciTech</addtitle><description>In this work, heat stable dry powders of oxytocin (OT) suitable for delivery by oral inhalation were prepared. The OT dry powders were prepared by spray drying using excipients chosen to promote OT stability including trehalose, isoleucine, polyvinylpyrrolidone, citrate (sodium citrate and citric acid), and zinc salts (zinc chloride and zinc citrate). Characterization by laser diffraction indicated that the OT dry powders had a median particle size of 2 μm, making them suitable for delivery by inhalation. Aerodynamic performance upon discharge from proprietary dry powder inhalers was evaluated by Andersen cascade impaction (ACI) and in an anatomically correct airway (ACA) model, and confirmed that the powders had excellent aerodynamic performance, with respirable fractions up to 77% (ACI, 30 L/min). Physicochemical characterization demonstrated that the powders were amorphous (X-ray diffraction) with high glass transition temperature (modulated differential scanning calorimetry, MDSC), suggesting the potential for stabilization of the OT in a glassy amorphous matrix. OT assay and impurity profile were conducted by reverse phase HPLC and liquid chromatography-mass spectrometry (LC-MS) after storage up to 32 weeks at 40°C/75%RH. Analysis demonstrated that OT dry powders containing a mixture of citrate and zinc salts retained more than 90% of initial assay after 32 weeks storage and showed significant reduction in dimers and trisulfide formation (up to threefold reduction compared to control).</description><subject>Administration, Inhalation</subject><subject>Aerosols - chemistry</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Calorimetry, Differential Scanning - methods</subject><subject>Chemistry, Pharmaceutical - methods</subject><subject>Desiccation - methods</subject><subject>Drug Compounding - methods</subject><subject>Drug Stability</subject><subject>Dry Powder Inhalers - methods</subject><subject>Excipients - chemistry</subject><subject>Hot Temperature</subject><subject>Nanoparticles - chemistry</subject><subject>Oxytocin - chemistry</subject><subject>Particle Size</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Powders - chemistry</subject><subject>Research Article</subject><subject>Trehalose - chemistry</subject><subject>X-Ray Diffraction - methods</subject><issn>1530-9932</issn><issn>1530-9932</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU9Lw0AQxRdRrFY_gBfJ0Ut0_2azF0HU2kKhgnpeNtlNm5Jm626i5tu7JbXUi3iagfebx8w8AC4QvEYYpjceYUxFDBGLIUE0hgfgBDECYyEIPtzrB-DU-yWEmCBBjsEAM84TkbITMB0b1cQvjcoqEz24Lnq2n9q4aPbVNTYv62hk3aqtVFPa2keFddGDqcoPE8isi2ZOVdGkXqgeOANHhaq8Od_WIXgbPb7ej-Pp7GlyfzeNc0ZZE-ssM5wmQhcZE0JTKjJEM8RVkBMocJJCg2GBRQ4TTWjOGS00UbjQWhcMQTIEt73vus1WRuembsIicu3KlXKdtKqUv5W6XMi5_ZA0SZLwsWBwtTVw9r01vpGr0uemqlRtbOsl4ikXnKWY_wMlaYpxSnBAUY_mznrvTLHbCEG5CUz2gckQmNwEJjenXO6fspv4SSgAuAd8kOq5cXJpW1eH9_7h-g30d6Fp</recordid><startdate>20151201</startdate><enddate>20151201</enddate><creator>Fabio, Karine</creator><creator>Curley, Kieran</creator><creator>Guarneri, Joseph</creator><creator>Adamo, Benoit</creator><creator>Laurenzi, Brendan</creator><creator>Grant, Marshall</creator><creator>Offord, Robin</creator><creator>Kraft, Kelly</creator><creator>Leone-Bay, Andrea</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20151201</creationdate><title>Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation</title><author>Fabio, Karine ; Curley, Kieran ; Guarneri, Joseph ; Adamo, Benoit ; Laurenzi, Brendan ; Grant, Marshall ; Offord, Robin ; Kraft, Kelly ; Leone-Bay, Andrea</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c545t-dbbe7469dfb599d449b14b17ac546092680e20f29c06d34c754fd3a2fdddf5103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Administration, Inhalation</topic><topic>Aerosols - chemistry</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Calorimetry, Differential Scanning - methods</topic><topic>Chemistry, Pharmaceutical - methods</topic><topic>Desiccation - methods</topic><topic>Drug Compounding - methods</topic><topic>Drug Stability</topic><topic>Dry Powder Inhalers - methods</topic><topic>Excipients - chemistry</topic><topic>Hot Temperature</topic><topic>Nanoparticles - chemistry</topic><topic>Oxytocin - chemistry</topic><topic>Particle Size</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Powders - chemistry</topic><topic>Research Article</topic><topic>Trehalose - chemistry</topic><topic>X-Ray Diffraction - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fabio, Karine</creatorcontrib><creatorcontrib>Curley, Kieran</creatorcontrib><creatorcontrib>Guarneri, Joseph</creatorcontrib><creatorcontrib>Adamo, Benoit</creatorcontrib><creatorcontrib>Laurenzi, Brendan</creatorcontrib><creatorcontrib>Grant, Marshall</creatorcontrib><creatorcontrib>Offord, Robin</creatorcontrib><creatorcontrib>Kraft, Kelly</creatorcontrib><creatorcontrib>Leone-Bay, Andrea</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>AAPS PharmSciTech</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fabio, Karine</au><au>Curley, Kieran</au><au>Guarneri, Joseph</au><au>Adamo, Benoit</au><au>Laurenzi, Brendan</au><au>Grant, Marshall</au><au>Offord, Robin</au><au>Kraft, Kelly</au><au>Leone-Bay, Andrea</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation</atitle><jtitle>AAPS PharmSciTech</jtitle><stitle>AAPS PharmSciTech</stitle><addtitle>AAPS PharmSciTech</addtitle><date>2015-12-01</date><risdate>2015</risdate><volume>16</volume><issue>6</issue><spage>1299</spage><epage>1306</epage><pages>1299-1306</pages><issn>1530-9932</issn><eissn>1530-9932</eissn><abstract>In this work, heat stable dry powders of oxytocin (OT) suitable for delivery by oral inhalation were prepared. The OT dry powders were prepared by spray drying using excipients chosen to promote OT stability including trehalose, isoleucine, polyvinylpyrrolidone, citrate (sodium citrate and citric acid), and zinc salts (zinc chloride and zinc citrate). Characterization by laser diffraction indicated that the OT dry powders had a median particle size of 2 μm, making them suitable for delivery by inhalation. Aerodynamic performance upon discharge from proprietary dry powder inhalers was evaluated by Andersen cascade impaction (ACI) and in an anatomically correct airway (ACA) model, and confirmed that the powders had excellent aerodynamic performance, with respirable fractions up to 77% (ACI, 30 L/min). Physicochemical characterization demonstrated that the powders were amorphous (X-ray diffraction) with high glass transition temperature (modulated differential scanning calorimetry, MDSC), suggesting the potential for stabilization of the OT in a glassy amorphous matrix. OT assay and impurity profile were conducted by reverse phase HPLC and liquid chromatography-mass spectrometry (LC-MS) after storage up to 32 weeks at 40°C/75%RH. Analysis demonstrated that OT dry powders containing a mixture of citrate and zinc salts retained more than 90% of initial assay after 32 weeks storage and showed significant reduction in dimers and trisulfide formation (up to threefold reduction compared to control).</abstract><cop>New York</cop><pub>Springer US</pub><pmid>25776985</pmid><doi>10.1208/s12249-015-0314-0</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1530-9932 |
ispartof | AAPS PharmSciTech, 2015-12, Vol.16 (6), p.1299-1306 |
issn | 1530-9932 1530-9932 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4666249 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Springer Nature - Complete Springer Journals; PubMed Central; Free Full-Text Journals in Chemistry |
subjects | Administration, Inhalation Aerosols - chemistry Biochemistry Biomedical and Life Sciences Biomedicine Biotechnology Calorimetry, Differential Scanning - methods Chemistry, Pharmaceutical - methods Desiccation - methods Drug Compounding - methods Drug Stability Dry Powder Inhalers - methods Excipients - chemistry Hot Temperature Nanoparticles - chemistry Oxytocin - chemistry Particle Size Pharmacology/Toxicology Pharmacy Powders - chemistry Research Article Trehalose - chemistry X-Ray Diffraction - methods |
title | Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T19%3A35%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Heat-Stable%20Dry%20Powder%20Oxytocin%20Formulations%20for%20Delivery%20by%20Oral%20Inhalation&rft.jtitle=AAPS%20PharmSciTech&rft.au=Fabio,%20Karine&rft.date=2015-12-01&rft.volume=16&rft.issue=6&rft.spage=1299&rft.epage=1306&rft.pages=1299-1306&rft.issn=1530-9932&rft.eissn=1530-9932&rft_id=info:doi/10.1208/s12249-015-0314-0&rft_dat=%3Cproquest_pubme%3E1787975827%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1738822832&rft_id=info:pmid/25776985&rfr_iscdi=true |